News and Events

Directorate Change

10 July 2019

Rasna today announces that Alex Martin has resigned as a director of Rasna Therapeutics, Inc. for personal reasons.  Mr. Martin’s resignation is not a result of any disagreement with the Company, the Company’s management or the Board of Directors.

Read more

Rasna Therapeutics, Inc. Announces Follow Up Phase II Clinical Data Confirming Efficacy of Actinomycin D in Patients with NPM1-mutated Acute Myeloid Leukemia

03 January 2018

  • Treatment with Actinomycin D (Act D) as a single drug achieved complete remission in 4 out of 9 evaluable patients (44.4%).

  • Treatment with Act D at 15 µg/kg/day for 5 days every 28 days (which defines one cycle) was well tolerated...

Read more